JP2022512863A5 - - Google Patents
Info
- Publication number
- JP2022512863A5 JP2022512863A5 JP2021523487A JP2021523487A JP2022512863A5 JP 2022512863 A5 JP2022512863 A5 JP 2022512863A5 JP 2021523487 A JP2021523487 A JP 2021523487A JP 2021523487 A JP2021523487 A JP 2021523487A JP 2022512863 A5 JP2022512863 A5 JP 2022512863A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition according
- seq
- inhibitor
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862754750P | 2018-11-02 | 2018-11-02 | |
| US62/754,750 | 2018-11-02 | ||
| PCT/US2019/059446 WO2020092937A1 (en) | 2018-11-02 | 2019-11-01 | Compositions and methods for treating brain injury |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512863A JP2022512863A (ja) | 2022-02-07 |
| JP2022512863A5 true JP2022512863A5 (enExample) | 2022-12-20 |
| JP7499760B2 JP7499760B2 (ja) | 2024-06-14 |
Family
ID=70459352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523487A Active JP7499760B2 (ja) | 2018-11-02 | 2019-11-01 | 脳損傷を治療するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200140533A1 (enExample) |
| EP (1) | EP3873525B1 (enExample) |
| JP (1) | JP7499760B2 (enExample) |
| AU (1) | AU2019370485B2 (enExample) |
| CA (1) | CA3118453A1 (enExample) |
| ES (1) | ES3015004T3 (enExample) |
| MX (1) | MX2021004819A (enExample) |
| WO (1) | WO2020092937A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201510316UA (en) | 2013-07-09 | 2016-01-28 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| US20240034775A1 (en) * | 2020-05-05 | 2024-02-01 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads | Compositions and methods for treating epilepsy |
| AU2021310926A1 (en) | 2020-07-23 | 2023-03-23 | Othair Prothena Limited | Anti-abeta antibodies |
| BR112023001942A2 (pt) * | 2020-08-06 | 2023-02-28 | Bioverativ Usa Inc | Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento |
| US20240420490A1 (en) * | 2021-10-19 | 2024-12-19 | Denali Therapeutics Inc. | Microglial cell morphometry |
| US12486322B2 (en) * | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
| MA71249A (fr) | 2022-06-24 | 2025-04-30 | Bioverativ Usa Inc. | Méthodes de traitement de maladies médiées par complément |
| CN121197154B (zh) * | 2025-11-13 | 2026-06-23 | 首都医科大学附属北京天坛医院 | Mac-1激动剂在制备治疗和/或缓解脑出血药物中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| WO1995005864A1 (en) | 1993-08-27 | 1995-03-02 | Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Convection-enhanced drug delivery |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| BRPI0518994A2 (pt) | 2004-12-31 | 2008-12-02 | Biogen Idec Inc | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas |
| US8568717B2 (en) | 2008-04-03 | 2013-10-29 | Vib Vzw | Single domain antibodies capable of modulating BACE activity |
| WO2010022149A1 (en) * | 2008-08-20 | 2010-02-25 | The Trustees Of The University Of Pennsylvania | Complement inhibitors for treatment of injury form intracerebral hemorrhage |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| US9181535B2 (en) | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
| WO2014066744A2 (en) * | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP2997045A4 (en) * | 2013-05-15 | 2016-11-23 | Annexon Inc | ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF |
| US9862777B2 (en) | 2013-05-28 | 2018-01-09 | Vib Vzw | Single domain antibodies against SOD1 and their use in medicine |
| SG11201510316UA (en) * | 2013-07-09 | 2016-01-28 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| PL3215527T3 (pl) * | 2014-11-05 | 2025-04-28 | Annexon, Inc. | Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie |
| EP3487531A4 (en) * | 2016-07-19 | 2020-03-25 | Annexon, Inc. | TREATMENT OF FRONTO-TEMPORAL DEMENTIA |
-
2019
- 2019-11-01 MX MX2021004819A patent/MX2021004819A/es unknown
- 2019-11-01 US US16/671,920 patent/US20200140533A1/en not_active Abandoned
- 2019-11-01 AU AU2019370485A patent/AU2019370485B2/en active Active
- 2019-11-01 CA CA3118453A patent/CA3118453A1/en active Pending
- 2019-11-01 EP EP19878411.8A patent/EP3873525B1/en active Active
- 2019-11-01 ES ES19878411T patent/ES3015004T3/es active Active
- 2019-11-01 WO PCT/US2019/059446 patent/WO2020092937A1/en not_active Ceased
- 2019-11-01 JP JP2021523487A patent/JP7499760B2/ja active Active
-
2023
- 2023-08-04 US US18/230,480 patent/US20240083989A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7837375B2 (ja) | ピログルタメートアミロイド－βに対する抗体及びその使用 | |
| US20210230269A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| US20250257127A1 (en) | Anti-DLL3 Antibodies and Uses Thereof | |
| JP7173618B2 (ja) | アルファ－シヌクレインに対する抗体およびその用途 | |
| JP2017186347A (ja) | 抗ｔｉｅ２抗体およびその使用 | |
| WO2018081642A1 (en) | Anti-apoe antibodies | |
| JP2019505166A5 (enExample) | ||
| JP2019504615A5 (enExample) | ||
| JP2022513050A5 (enExample) | ||
| US11643458B2 (en) | Monoclonal antibody against Nav1.7 | |
| CN114729036B (zh) | 抗干细胞因子抗体及其使用方法 | |
| JP2023524819A5 (enExample) | ||
| JP2025539937A (ja) | 抗ｐａｐｐ－ａ抗体及びその使用方法 | |
| CN111886024B (zh) | 抗tip-1抗体及其用途 | |
| WO2020125744A1 (zh) | 双特异性蛋白 | |
| JP2024534313A (ja) | 抗ｃｇｒｐ抗体の投薬及びスクリーニング方法 | |
| CN120058937B (zh) | 一种靶向lgr4的纳米抗体nb21及其在抗肥胖治疗中的应用 | |
| US20250163136A1 (en) | Anti-transthyretin (ttr) binding proteins and uses thereof | |
| CN120035606A (zh) | 一种治疗实体瘤的方法 | |
| CN120118184A (zh) | 靶向Tau的特异性结合蛋白及其应用 | |
| HK40114489A (en) | Compositions and methods for treating huntington's disease | |
| CN119677537A (zh) | 用于治疗狼疮性肾炎的组合物和方法 | |
| JP2025503545A (ja) | ハンチントン病を治療するための組成物及び方法 | |
| CN115925952A (zh) | 抗叶酸受体1抗体及其用途 | |
| HK40039992A (en) | Anti-dll3 antibodies and uses thereof |